Patients are the key to disruptive innovation in cancer. Why aren’t they at the table?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Today’s traditional research model relies on incremental innovation that builds upon the shoulders of other researchers’ work, making small but steady strides. Occasionally, leaps are made by researchers who develop new classes of therapy such as stem cell transplant or CAR-T immunotherapy. But cancer patients may not have the luxury to wait 20 years for the traditional scientific process to evolve for their cancer. They can’t wait for a cure.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jenny Ahlstrom
Founder and CEO of HealthTree
Table of Contents

YOU MAY BE INTERESTED IN

Jenny Ahlstrom
Founder and CEO of HealthTree

Login